Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833436 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14815215 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14833231 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30337582 | 0.76 | SMN1; SMN2 (0.45) | L3MBTL1KMT2ASMN1; SMN2HPGDTSHR | |
| SCHEMBL31435145 | 0.75 | THRB (0.55) | THRB | |
| SCHEMBL4555734 | 0.74 | THRB (0.60) | THRB | |
| SCHEMBL30337144 | 0.72 | SLC6A2 (0.44) | L3MBTL1KMT2ASMN1; SMN2POLBCYP2D6 | |
| SCHEMBL30337246 | 0.71 | ENPP2 (0.47) | L3MBTL1KMT2ASMN1; SMN2CYP2D6THRB | |
| SCHEMBL13673303 | 0.70 | KMT2A (0.52) | KMT2AMEN1SMN1; SMN2HPGDTSHR | |
| SCHEMBL31190825 | 0.70 | HPGD (0.64) | KMT2ASMN1; SMN2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452982-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | Incyte Corporation (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118660889-A | Salt and solid forms of FGFR inhibitors and methods of making the same | 因赛特公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-3083573-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023122134-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | INCYTE CORPORATION (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122134-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | INCYTE CORPORATION (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192722-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192722-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192722-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-10000484-B2 | Inhibitors of the renal outer medullary potassim channel | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3083573-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160304515-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| WO-2015095097-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| WO-2013049164-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000484-B2 | Inhibitors of the renal outer medullary potassim channel | KCNJ11, KCNJ1, KCNJ2 | KDM4E 3635/4885L3MBTL1 3286/4885KMT2A 2551/4885 |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | KDM4E 3058/4885L3MBTL1 2030/4885KMT2A 2999/4885 |
| US-20230192722-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | FGFR1, FGFR3, FGFR4 | KDM4E 232/4885L3MBTL1 2425/4885KMT2A 595/4885 |
| US-20160304515-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KDM4E 3635/4885L3MBTL1 3286/4885KMT2A 2551/4885 |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | KDM4E 3640/4885L3MBTL1 2446/4885KMT2A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.